Description
An understanding of the market for anesthesia could be worthwhile to any pharmaceutical marketer and any equity company investing or consulting in this area. Anesthesia markets are in one sense simple: growth in these drugs are correlated to prevalence and incidence in disease, and the resulting increase in procedure volumes. But as this market continues to grow, increased competition is steadily escalating in the United States and Europe, which is encouraging more participation in other areas of the world. New products in development may change the market landscape dramatically.
This Kalorama Information report – Anesthesia Drugs: Worldwide Markets – focuses on three primary segments of anesthesia:
- General Anesthesia (Inhalation, Parenteral and Rectal)
- Local Anesthesia (Topical, Transdermal, Parenteral)
- Adjunctive Therapies in Anesthesia
The report covers both currently marketed and late stage development anesthesia drugs in detail. Revenues for each segment were generated using dollar and unit sales for each product.
The report includes statistical information for surgical procedures, incidence of conditions requiring surgery, and other relevant information. Statistical information is presented as a worldwide overview, with special emphasis on the U.S. The market segments provide an overview, description of products on the market, description of products in development, market estimates and forecasts, and competitive analysis of leading providers. The report also includes current issues and trends affecting the industry.
The issues and trends addressed in the anesthesia drug market include:
- Regulation of Anesthesia Drugs
- Dentistry and Anesthesia
- Anesthesia and Pediatric Applications
- Anesthesia and Benefits to Depressed Patients
- Anesthesia and Sleep
- Gender Differences in Anesthesia Reaction
- Trends in Conscious Sedation
The information for this report was gathered using both primary and secondary research including comprehensive research of secondary sources such as company literature, databases, investment reports, and medical and business journals. Telephone interviews and email correspondence were the primary method of gathering information. For the purpose of this study
Kalorama Information conducted interviews with more than 50 key industry officials, consultants, health care providers, and government personnel. These sources were the primary basis in gathering information specifically relating to revenue and market share data presented in this report. Specific interviews with pharmaceutical company representatives included marketing directors, division managers, and product representatives.
All market data pertains to the world market at the manufacturers’ level. The base year for data was 2006. Historical data is provided for the years 2004 and 2005, with forecast data provided for 2007 through 2011. Compound annual growth rates (CAGRs) are provided for the 2004-2006, 2006-2011 and 2004-2011 periods for each industry segment covered. Competitive analysis is provided for the year 2006 with a projected competitive analysis for 2011.
The forecasted market analysis for 2007-2011 is based on probability of approval and sales of products in late stage development, product marketing, and demographic trends.
As part of its market coverage, the following companies were profiled in this report:
- Abbott Laboratories
- Abraxis BioScience, Inc.
- Anesiva, Inc.
- Baxter International, Inc
- B. Braun Melsungen AG
- Dentsply International, Inc.
- Endo Pharmaceuticals Holdings, Inc.
- Hospira, Inc.
- MGI Pharma, Inc
- Minrad International, Inc.
- Organon N.V.
- Roche
- SkyePharma plc
- TEVA
